newsfilter
← Latest News
GlobeNewswire·

Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)

TELO
  • Telomir Pharmaceuticals announced peer-reviewed preclinical research showing Telomir-Zn improved visual function, restored retinal structure, & reduced mitochondrial oxidative stress in an age-related macular degeneration (AMD) model.
  • The study demonstrates that Telomir-Zn modulates intracellular metal homeostasis to influence disease pathways across different biological settings beyond oncology.
  • In the AMD model, treatment restored altered DNA methylation patterns & increased relative telomeric DNA content dose-dependently toward healthy profiles.
  • Mechanistic studies revealed Telomir-Zn reduced intracellular labile iron & inhibited iron-dependent Jumonji C histone demethylases (KDMs), particularly KDM5B with an IC50 of 63 nM.
  • Treatment for 14 days improved central visual response, moving-object tracking, & light intensity adaptation while restoring thickness in multiple retinal layers including the outer & inner nuclear layers.
  • Telomir-Zn reduced brain reactive oxygen species as a surrogate for mitochondrial oxidative stress & attenuated metal-induced calcium dysregulation in human ARPE-19 retinal pigment epithelial cells.
  • The company's clinical development remains focused on oncology, advancing Telomir-Zn under an FDA-cleared Investigational New Drug application for a Phase 1/2 trial in advanced or metastatic triple-negative breast cancer.
  • The findings were published in the International Journal of Molecular Sciences, titled "Targeted Intracellular Metal Modulation Attenuates Oxidative Stress and Preserves Retinal Integrity and Function in a Zebrafish Model of Mitochondrial Dysfunction and Age-Related Retinal Degeneration."
  • Management stated that while oncology is the priority, the common biology of intracellular metal homeostasis & epigenetic regulation suggests potential platform opportunities for Telomir-Zn in other diseases.